BRPI0800991A2 - composiÇÕes para uso no escurecimento da pele - Google Patents

composiÇÕes para uso no escurecimento da pele

Info

Publication number
BRPI0800991A2
BRPI0800991A2 BRPI0800991-0A BRPI0800991A BRPI0800991A2 BR PI0800991 A2 BRPI0800991 A2 BR PI0800991A2 BR PI0800991 A BRPI0800991 A BR PI0800991A BR PI0800991 A2 BRPI0800991 A2 BR PI0800991A2
Authority
BR
Brazil
Prior art keywords
darkening
skin
compositions
glycerophospholipids
fatty acid
Prior art date
Application number
BRPI0800991-0A
Other languages
English (en)
Inventor
Connie Baozhen Lin
Miri Seiberg
Original Assignee
Johnson & Johnson Consumer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Consumer filed Critical Johnson & Johnson Consumer
Publication of BRPI0800991A2 publication Critical patent/BRPI0800991A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/04—Preparations for care of the skin for chemically tanning the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSIÇÕES PARA USO NO ESCURECIMENTO DA PELE. A presente invenção apresenta glicerofosfolipídios que tem uma única porção de ácido graxo e o uso desses no escurecimento da pele.
BRPI0800991-0A 2007-03-29 2008-03-31 composiÇÕes para uso no escurecimento da pele BRPI0800991A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/693,023 US20080241085A1 (en) 2007-03-29 2007-03-29 Compositions for use in darkening the skin

Publications (1)

Publication Number Publication Date
BRPI0800991A2 true BRPI0800991A2 (pt) 2008-11-25

Family

ID=39561971

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0800991-0A BRPI0800991A2 (pt) 2007-03-29 2008-03-31 composiÇÕes para uso no escurecimento da pele

Country Status (3)

Country Link
US (1) US20080241085A1 (pt)
EP (1) EP1974773A3 (pt)
BR (1) BRPI0800991A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8084504B2 (en) 2009-10-02 2011-12-27 Johnson & Johnson Consumer Companies, Inc. High-clarity aqueous concentrates of 4-hexylresorcinol
US8906432B2 (en) 2009-10-02 2014-12-09 Johnson & Johnson Consumer Companies, Inc. Compositions comprising an NFκB-inhibitor and a non-retinoid collagen promoter
CA2774026C (en) 2009-10-02 2018-04-24 Johnson & Johnson Consumer Companies, Inc. Compositions comprising an anti-inflammatory blend
US20110081305A1 (en) * 2009-10-02 2011-04-07 Steven Cochran Compositions comprising a skin-lightening resorcinol and a skin darkening agent
US20110081430A1 (en) 2009-10-02 2011-04-07 Simarna Kaur COMPOSITIONS COMPRISING AN NFkB-INHIBITOR AND A TROPOELASTIN PROMOTER
US9475709B2 (en) 2010-08-25 2016-10-25 Lockheed Martin Corporation Perforated graphene deionization or desalination
US9610546B2 (en) 2014-03-12 2017-04-04 Lockheed Martin Corporation Separation membranes formed from perforated graphene and methods for use thereof
US10653824B2 (en) 2012-05-25 2020-05-19 Lockheed Martin Corporation Two-dimensional materials and uses thereof
US10980919B2 (en) 2016-04-14 2021-04-20 Lockheed Martin Corporation Methods for in vivo and in vitro use of graphene and other two-dimensional materials
US9744617B2 (en) 2014-01-31 2017-08-29 Lockheed Martin Corporation Methods for perforating multi-layer graphene through ion bombardment
US10203295B2 (en) 2016-04-14 2019-02-12 Lockheed Martin Corporation Methods for in situ monitoring and control of defect formation or healing
US10418143B2 (en) 2015-08-05 2019-09-17 Lockheed Martin Corporation Perforatable sheets of graphene-based material
US9834809B2 (en) 2014-02-28 2017-12-05 Lockheed Martin Corporation Syringe for obtaining nano-sized materials for selective assays and related methods of use
US10376845B2 (en) 2016-04-14 2019-08-13 Lockheed Martin Corporation Membranes with tunable selectivity
US20140086859A1 (en) 2012-09-24 2014-03-27 Johnson & Johnson Consumer Companies, Inc. Low oil compositions comprising a 4-substituted resorcinol and a high carbon chain ester
US9592475B2 (en) 2013-03-12 2017-03-14 Lockheed Martin Corporation Method for forming perforated graphene with uniform aperture size
US9572918B2 (en) 2013-06-21 2017-02-21 Lockheed Martin Corporation Graphene-based filter for isolating a substance from blood
JP2017510461A (ja) 2014-01-31 2017-04-13 ロッキード マーティン コーポレイションＬｏｃｋｈｅｅｄ Ｍａｒｔｉｎ Ｃｏｒｐｏｒａｔｉｏｎ 広幅イオン場を用いる二次元材料の穿孔
AU2015210875A1 (en) 2014-01-31 2016-09-15 Lockheed Martin Corporation Processes for forming composite structures with a two-dimensional material using a porous, non-sacrificial supporting layer
WO2015138771A1 (en) 2014-03-12 2015-09-17 Lockheed Martin Corporation Separation membranes formed from perforated graphene
SG11201701654UA (en) 2014-09-02 2017-04-27 Lockheed Corp Hemodialysis and hemofiltration membranes based upon a two-dimensional membrane material and methods employing same
AU2016303049A1 (en) 2015-08-06 2018-03-01 Lockheed Martin Corporation Nanoparticle modification and perforation of graphene
CA3020880A1 (en) 2016-04-14 2017-10-19 Lockheed Martin Corporation Selective interfacial mitigation of graphene defects
SG11201809015WA (en) 2016-04-14 2018-11-29 Lockheed Corp Two-dimensional membrane structures having flow passages
SG11201808962RA (en) 2016-04-14 2018-11-29 Lockheed Corp Method for treating graphene sheets for large-scale transfer using free-float method

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690825A (en) 1985-10-04 1987-09-01 Advanced Polymer Systems, Inc. Method for delivering an active ingredient by controlled time release utilizing a novel delivery vehicle which can be prepared by a process utilizing the active ingredient as a porogen
JPS6295132A (ja) * 1985-10-21 1987-05-01 Nippon Saafuakutanto Kogyo Kk 多価アルコ−ル中油型乳化組成物
US5145675A (en) 1986-03-31 1992-09-08 Advanced Polymer Systems, Inc. Two step method for preparation of controlled release formulations
US5218079A (en) 1990-05-18 1993-06-08 Yale University Soluble melanin
US5225435A (en) 1990-05-18 1993-07-06 Yale University Soluble melanin
US5216116A (en) 1990-05-18 1993-06-01 Yale University Soluble melanin
US5227459A (en) 1990-05-18 1993-07-13 Yale University Synthetic melanin
US5744125A (en) 1993-08-19 1998-04-28 Yale University Cosmetic melanins
US5716814A (en) * 1996-02-02 1998-02-10 Biomolecular Products, Inc. Methods for making lysophosphatidylcholine
US6284234B1 (en) 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
JP2000344651A (ja) * 1999-06-01 2000-12-12 Shiseido Co Ltd 皮膚外用剤
US6797697B2 (en) 2001-05-21 2004-09-28 Johnson & Johnson Consumer Companies, Inc. Composition containing a peptide and a pigment and the use thereof in darkening the skin
US7081442B2 (en) 2001-05-21 2006-07-25 Johnson & Johnson Consumer Companies, Inc. Composition containing a peptide and a pigment and the use thereof in darkening the skin
WO2003047543A1 (en) * 2001-10-05 2003-06-12 Procyte Corporation Methods for the treatment of hyperpigmentation of skin
US7025951B2 (en) 2002-06-18 2006-04-11 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for darkening the skin
JP2004269433A (ja) * 2003-03-10 2004-09-30 Rasheru Seiyaku Kk 化粧料組成物
JP4015631B2 (ja) * 2004-02-19 2007-11-28 株式会社 伊藤園 容器詰緑茶飲料の製造方法
US7749286B2 (en) * 2006-05-01 2010-07-06 Advanced Cosmetic Technologies, Llc Composition for dyeing keratin fibers and a method of dyeing hair using same

Also Published As

Publication number Publication date
EP1974773A3 (en) 2011-04-06
EP1974773A2 (en) 2008-10-01
US20080241085A1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
BRPI0800991A2 (pt) composiÇÕes para uso no escurecimento da pele
SV2009003335A (es) Formulaciones para el cancer
SV2011003838A (es) 4-fenil-1h-pirazoles insecticidas
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
MX352328B (es) Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.
ECSP13011139A (es) Anticuerpos contra la angiopoyetina 2 humana
CY1119784T1 (el) Ακετυλιωμενες σαλικυλικες ενωσεις λιπαρου οξεος και οι χρησεις αυτων
CL2018002703A1 (es) Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr). (divisional solicitud 201401291)
ECSP10010344A (es) Azolilmetiloxiranos, su uso y agentes que los contienen
BRPI0815170A2 (pt) Composição farmacêutica que compreende um inibidor de sglt 2
GT200900292A (es) "inhibidores de cinasa p70 s6"
EP2435057A4 (en) COMPOSITIONS AND METHOD FOR MODULATING A LIPID COMPOSITION
NI201200038A (es) Conjugados de niacina y ácidos grasos y sus usos
MX338712B (es) Composicion farmaceutica que comprende linagliptina y opcionalmente un inhibidor de sglt2, y usos de la misma.
BRPI0915877A2 (pt) seções de uma apresentação que tem propriedade definíveis por usuário
GT201300186A (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
CO6571913A2 (es) Derivados de fumarato de ácido graso y sus usos
BRPI0821496A2 (pt) Composições nanopartículas que proporcionam aprimorada coloração para formulações cosméticas
BRPI1106572B8 (pt) Composições que compreendem um retinoide e um inibidor de nfkb e seus métodos de uso
BR112014009376A2 (pt) composições
BRPI0715073A8 (pt) métodos e composições para inibir a angiogênese
CO6630181A2 (es) Composiciones y métodos para uso de anticuerpos terapéuticos de lrp6( proteina relacionada con lipoproteínas de baja densidad 6)
AR083268A1 (es) Conjugado de naloxol-peg cristalino
BRPI0702163A (pt) composições de toner e métodos
MX2009002224A (es) Composicion a base de xantoxilina y su utilizacion en cosmetica.

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 4A ANUIDADE.